News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
855,827 Results
Type
Article (87231)
Company Profile (738)
Press Release (767844)
Multimedia
Podcasts (188)
Webinars (28)
Section
Business (232684)
Career Advice (4140)
Deals (39833)
Drug Delivery (139)
Drug Development (91125)
Employer Resources (203)
FDA (18225)
Job Trends (17407)
News (396670)
Policy (39826)
Tag
Academia (2995)
Academic (1)
Accelerated approval (27)
Adcomms (29)
Allergies (113)
Alliances (56793)
ALS (146)
Alzheimer's disease (1716)
Antibody-drug conjugate (ADC) (278)
Approvals (18325)
Artificial intelligence (426)
Autoimmune disease (130)
Automation (26)
Bankruptcy (402)
Best Places to Work (12512)
BIOSECURE Act (23)
Biosimilars (195)
Biotechnology (455)
Bladder cancer (136)
Brain cancer (49)
Breast cancer (504)
Cancer (3997)
Cardiovascular disease (283)
Career advice (3562)
Career pathing (40)
CAR-T (277)
CDC (36)
Celiac Disease (1)
Cell therapy (719)
Cervical cancer (29)
Clinical research (75719)
Collaboration (1424)
Company closure (4)
Compensation (913)
Complete response letters (59)
COVID-19 (2918)
CRISPR (80)
C-suite (627)
Cystic fibrosis (137)
Data (5060)
Decentralized trials (2)
Denatured (69)
Depression (98)
Diabetes (322)
Diagnostics (6934)
Digital health (20)
Diversity (11)
Diversity, equity & inclusion (49)
Drug discovery (226)
Drug pricing (148)
Drug shortages (19)
Duchenne muscular dystrophy (188)
Earnings (97815)
Editorial (52)
Employer branding (25)
Employer resources (173)
Events (132325)
Executive appointments (805)
FDA (20379)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (6)
Frontotemporal dementia (21)
Funding (1172)
Gene editing (171)
Generative AI (42)
Gene therapy (563)
GLP-1 (903)
Government (5307)
Grass and pollen (4)
Guidances (269)
Healthcare (20769)
HIV (38)
Huntington's disease (43)
IgA nephropathy (73)
Immunology and inflammation (252)
Immuno-oncology (42)
Indications (60)
Infectious disease (3127)
Inflammatory bowel disease (196)
Inflation Reduction Act (14)
Influenza (92)
Intellectual property (174)
Interviews (816)
IPO (17791)
IRA (45)
Job creations (5196)
Job search strategy (2866)
Kidney cancer (16)
Labor market (86)
Layoffs (632)
Leadership (36)
Legal (10088)
Liver cancer (84)
Longevity (11)
Lung cancer (556)
Lymphoma (318)
Machine learning (36)
Management (66)
Manufacturing (634)
MASH (153)
Medical device (14403)
Medtech (14426)
Mergers & acquisitions (22661)
Metabolic disorders (993)
Multiple sclerosis (137)
NASH (22)
Neurodegenerative disease (298)
Neuropsychiatric disorders (65)
Neuroscience (2753)
NextGen: Class of 2025 (7680)
Non-profit (5072)
Now hiring (61)
Obesity (479)
Opinion (317)
Ovarian cancer (139)
Pain (138)
Pancreatic cancer (153)
Parkinson's disease (238)
Partnered (31)
Patents (362)
Patient recruitment (356)
Peanut (55)
People (66056)
Pharmaceutical (133)
Pharmacy benefit managers (19)
Phase I (23455)
Phase II (32941)
Phase III (24718)
Pipeline (3367)
Policy (271)
Postmarket research (3544)
Preclinical (10565)
Press Release (72)
Prostate cancer (187)
Psychedelics (47)
Radiopharmaceuticals (269)
Rare diseases (710)
Real estate (7419)
Recruiting (80)
Regulatory (27916)
Reports (61)
Research institute (2686)
Resumes & cover letters (651)
Rett syndrome (18)
RNA editing (16)
RSV (61)
Schizophrenia (132)
Series A (213)
Series B (144)
Service/supplier (25)
Sickle cell disease (83)
Special edition (26)
Spinal muscular atrophy (171)
Sponsored (46)
Startups (4316)
State (2)
Stomach cancer (13)
Supply chain (71)
Tariffs (73)
The Weekly (117)
Vaccines (970)
Venture capital (76)
Weight loss (320)
Women's health (63)
Worklife (21)
Date
Last 7 days (185)
Last 30 days (1688)
Last 365 days (25531)
2025 (25475)
2024 (34033)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1277)
Alabama (79)
Alaska (6)
Arizona (282)
Arkansas (8)
Asia (50940)
Australia (8970)
California (9128)
Canada (2368)
China (964)
Colorado (279)
Connecticut (370)
Delaware (274)
Europe (116544)
Florida (1181)
Georgia (244)
Hawaii (3)
Idaho (65)
Illinois (618)
India (50)
Indiana (428)
Iowa (19)
Japan (310)
Kansas (130)
Kentucky (23)
Louisiana (13)
Maine (59)
Maryland (1204)
Massachusetts (6895)
Michigan (238)
Minnesota (433)
Mississippi (5)
Missouri (76)
Montana (27)
Nebraska (28)
Nevada (99)
New Hampshire (53)
New Jersey (2430)
New Mexico (28)
New York (2419)
North Carolina (1349)
North Dakota (9)
Northern California (4414)
Ohio (239)
Oklahoma (18)
Oregon (48)
Pennsylvania (1773)
Puerto Rico (19)
Rhode Island (31)
South America (1652)
South Carolina (13)
South Dakota (1)
Southern California (3514)
Tennessee (55)
Texas (1282)
United States (32008)
Utah (197)
Vermont (1)
Virginia (158)
Washington D.C. (51)
Washington State (772)
West Virginia (2)
Wisconsin (70)
855,827 Results for "abilita bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Abilita Bio Changes Name to Abilita Therapeutics and Appoints Joel Edwards as Chief Business Officer
Abilita Bio, a leader in enabling the discovery of membrane protein-targeted therapeutics, announced today the company changed its name to Abilita Therapeutics.
June 1, 2023
·
3 min read
Mergers & acquisitions
How Akero’s MASH Success Drove Roche’s $3.5B Takeout of 89bio
Regulatory documents show how 89bio’s board pushed Roche hard for a deal valued at $20 per share in upfront and milestone payments.
October 2, 2025
·
3 min read
·
Annalee Armstrong
Earnings
‘We’re Not Done’: Roche Plans To Sustain Dealmaking Pace After 89bio
Roche has already signed several high-ticket deals this year, including the $3.5 billion acquisition of 89bio and Genentech’s $2.1 billion molecular glue pact with Orionis Biosciences.
October 23, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics
December 19, 2024
·
3 min read
Press Releases
Abilita Therapeutics and Orion Announce Research Collaboration to Develop Next-Generation Antibody Therapeutics in the Areas of Oncology and Pain
December 18, 2024
·
3 min read
Press Releases
New Research Highlights Syntax Bio’s Platform for Simple Yet Powerful Programming of Human Stem Cells
December 9, 2025
·
3 min read
Press Releases
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
December 19, 2025
·
6 min read
Press Releases
XOMA Royalty Enters into Agreement to Acquire Generation Bio
December 16, 2025
·
10 min read
Press Releases
Vor Bio Announces $150 Million Private Placement
December 16, 2025
·
4 min read
Press Releases
Precise Bio Achieves World’s First 3D-Bio-Printed Corneal Implant
November 20, 2025
·
4 min read
1 of 85,583
Next
